torres wrote:I pay $246.99 a month. It's a scary bill but BCBS pays 90% of the Tysabri infusion which is $5,076.26 a month so I can't complain.
for a drug that's efficacy is questionable at least
At 13 infusions required a year, that means a cost of almost $ 66,000 per patient
Natalizumab reduced the rate of clinical relapse at one year by 68 percent
Truth is,Tysabri's efficacy is proven 68% superior.
[/color][color=blue]Another truth, at $2184.62 per vial (wholesale) x's 13 infusions per year, that's equivalent to $28,400.06 per year, with most ins. co's covering same as an outpatient procedure. It's the infusion centers are price gouging the ins. co's and the patients. And when most fall in line with what is reasonable to charge, don't be surprised if the ones doing the price gouging now are left in the dust with lost patients, lost dr. referrals, lost ins. payments, etc.
msladyinca wrote:[color=blue]Personally, I wasn't quoting Biogen, I was quoting the findings of the New England Journal of Medicine...you can review them for yourself to answer your own questions - it's called "Due Diligence":
Users browsing this forum: No registered users